logo
From Promise To Practice: Why Technology Breakthroughs Struggle To Take Hold In Healthcare

From Promise To Practice: Why Technology Breakthroughs Struggle To Take Hold In Healthcare

Forbes28-07-2025
Sonali Bloom is CEO of 20/20 Onsite.
There is no shortage of innovation in healthcare. From AI-driven diagnostics to virtual reality platforms to telemedicine, keeping pace with new technology is daunting. Yet despite billions in funding, much of this new tech doesn't make it past press releases. It doesn't reach the front lines—primarily, from my perspective, due to adoption failure.
It's not that healthcare has an innovation problem. It has an implementation problem.
In our work supporting decentralized clinical trials by collaborating with pharma sponsors, sites and CROs, we've had a front-row seat to this innovation paradox. Here are a few things we've learned along the way that actually make technology adoption work.
Barriers To New Technology Adoption In Healthcare
Healthcare isn't one system. We all know it's a fragmented web of stakeholders with conflicting incentives. Sponsors want efficiency and data integrity. Sites want streamlined workflows. Patients want comfort and clarity. This fragmentation can result in even the best tech getting caught in limbo.
Healthcare requires safety and precision, which come at the cost of speed and agility. Every new platform or device must meet strict compliance standards. This positive feature of the healthcare system tends to slow the pace of adoption, especially for newer technologies without a track record of success.
Clinics and research sites are built around repeatable routines. Introducing new tech can mean changing how things are done, which can halt everything. We all know time is money, and downtime (or the thought of downtime) drops adoption rates, especially if extra steps are needed in the usual routine.
After years of transformation promises, many clinicians and trial staff are skeptical of 'the next big thing.' They're exhausted, overextended and hesitant to invest time in technology that doesn't clearly indicate how it will make their life or routine easier, more efficient or more accurate.
The Most Common Pitfalls
Just because you have excellent tech doesn't mean you can drop a new platform into a clinic and expect seamless adoption. Even the best-designed tools can fail without hands-on training, clear protocols and responsive support. This cannot be overstated.
If a new technology doesn't align tightly with a study's protocol or regulatory goals, it creates confusion. Trial sites will default to what's familiar and known to work, not what's new.
Change is hard. It requires taking time to pause, onboard and adopt change. Adoption is ultimately a behavior-change challenge, not just a deployment. Your tech won't be used if it doesn't make life easier for the people using it.
The Adoption Playbook
After working on dozens of clinical trials in our corner of the healthcare sector, we've identified a few practices that have helped improve adoption success.
The question isn't, 'What can this technology do?' Rather, ask, 'How will someone use this at 9:30 a.m. on a busy clinic day?' Thinking through the user experience during daily tasks will help build real-world utility.
The best technology feels invisible. It slides into existing workflows, not around them. I've found that adoption skyrockets when the new process requires minimal workflow disruption for implementation.
With tech adoption in our corner of the healthcare world, trial sites are the engine of clinical research. That means early involvement, feedback and ongoing support. You can't outsource adoption to the people at the end of the chain.
It's not enough to prove something works once, though that is a start. The goal should be repeatability. That requires documentation, training modules, feedback loops and scalable support.
Case In Point: Adoption In A Neurology Trial
In recent neurological trials, we helped operationalize a novel assessment technology with strong clinical potential that had a few real-world implementation challenges. Our job wasn't just to deliver the tool, but to provide enablement. This included:
• Standardized training materials across all trial sites.
• On-site and virtual onboarding for clinicians.
• A custom integration plan that aligned with visit flow.
• Ongoing troubleshooting and feedback collection.
We aimed to treat operationalization as a core part of adoption, not an afterthought. This helped ensure the technology wasn't just evaluated but also implemented and utilized.
Pairing Innovation With Adoption
In the race to revolutionize healthcare, the real winners won't be the companies with the flashiest tech. The real winners will be those who develop strategies to make their technology usable in the real world, with real people. In healthcare, innovation doesn't win. Innovation plus implementation does.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)
Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

Yahoo

time22 minutes ago

  • Yahoo

Piper Sandler Reiterates a Buy Rating on UnitedHealth Group (UNH)

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best stocks to invest in for beginners. Piper Sandler analyst Jessica Tassan reiterated a Buy rating on UnitedHealth Group Incorporated (NYSE:UNH) on August 5, setting a price target of $280.00. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) reported that its Q2 2025 revenue underwent a $12.8 billion year-over-year growth to $111.6 billion, attributed primarily to growth within Optum and UnitedHealthcare. Earnings from operations for the quarter were $5.2 billion, while adjusted net earnings were $4.08 per share. Management reported a full year 2025 revenue outlook in the $445.5 billion to $448.0 billion range, with a full year 2025 earnings outlook of at least $14.65 per share. UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Jim Cramer on International Business Machines: 'I Think They Have the Lead in Quantum'
Jim Cramer on International Business Machines: 'I Think They Have the Lead in Quantum'

Yahoo

time22 minutes ago

  • Yahoo

Jim Cramer on International Business Machines: 'I Think They Have the Lead in Quantum'

International Business Machines Corporation (NYSE:IBM) is one of the stocks Jim Cramer shed light on. A caller asked for Cramer's thoughts on the company, and he remarked: 'Okay, I didn't think IBM's quarter… was all that bad at all. I think you have a major opportunity down here because I think that we're going to start talking about IBM and quantum. I think they have the lead in quantum, and I think quantum really does matter. They have a great software package. They're doing so many things that are good. Tauke / International Business Machines Corporation (NYSE:IBM) provides integrated solutions across software, consulting, infrastructure, and financing. The company offers hybrid cloud and AI platforms, technology services, and IT financing solutions. While we acknowledge the potential of IBM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Jim Cramer on UnitedHealth: 'It Could Come Back'
Jim Cramer on UnitedHealth: 'It Could Come Back'

Yahoo

time22 minutes ago

  • Yahoo

Jim Cramer on UnitedHealth: 'It Could Come Back'

UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer shed light on. Cramer showed a slight bit of optimism toward the company as he said: 'I think UnitedHealth's going to work here… I think it's going to work. I really do. Look, I'm not a believer. I don't like the fact that they had shenanigans, but I will say this: I think that the company is run by a very good CEO. It could come back.' Ken Wolter/ UnitedHealth Group Incorporated (NYSE:UNH) provides health benefits, pharmacy care, care delivery, and health management services. In addition, the company offers data analytics and technology-driven solutions for individuals, employers, governments, and health systems. During the August 7 episode, when a caller inquired about the company stock, Cramer responded: 'I have long known, this is something I learned probably in my second decade of trading or investing: You do not buy or sell something where you have no idea what is really happening. And at UnitedHealth, there isn't anyone other than the CEO and probably 52,000 lawyers who has any idea what's going on.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store